Alexis Talbot (A Talbot)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 12

Top Topics

Multiple Myeloma

Mesenchymal Stem Cells

Acute Lymphoblastic Leukemia

Top Venues

Cancer immunology research

Nature biotechnology

The Journal of rheumatology

This page only lists publications with an associated author ORCID identifier.

Publications

Nathalie Roders, Cecilia Nakid-Cordero, Fabio Raineri, Maxime Fayon, Audrey Abecassis, Caroline Choisy, Elisabeth Nelson, Claire Maillard, David Garrick, Alexis Talbot, Jean-Paul Fermand, Bertrand Arnulf, Jean-Christophe Bories
Dual Chimeric Antigen Receptor T Cells Targeting CD38 and SLAMF7 with Independent Signaling Demonstrate Preclinical Efficacy and Safety in Multiple Myeloma. Cancer immunology research 12 (4) (2024)
F Theves, C Lahuna, Thibault Mahevas, S Harel, B Royer, V Lemiale, A Brignier, N Parquet, Marie Jachiet, Jean-David Bouaziz, D Elessa, B Arnulf, Alexis Talbot
Plasma cell-directed therapies induce profound clinical and durable responses in patients with severe or relapsed/refractory scleromyxedema. Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Nathalie Roders, Cecilia Nakid-Cordero, Fabio Raineri, Maxime Fayon, Audrey Abecassis, Caroline Choisy, Elisabeth Nelson, Claire Maillard, David Garrick, Alexis Talbot, Jean-Paul Fermand, Bertrand Arnulf, Jean-Christophe Bories
Dual chimeric antigen receptor T cells targeting CD38 and SLAMF7 with independent signalling demonstrate preclinical efficacy and safety in Multiple Myeloma. Cancer immunology research (2024)
Matthew T Witkowski, Soobeom Lee, Eric Wang, Anna K Lee, Alexis Talbot, Chao Ma, Nikolaos Tsopoulidis, Justin Brumbaugh, Yaqi Zhao, Kathryn G Roberts, Simon J Hogg, Sofia Nomikou, Yohana E Ghebrechristos, Palaniraja Thandapani, Charles G Mullighan, Konrad Hochedlinger, Weiqiang Chen, Omar Abdel-Wahab, Justin Eyquem, Iannis Aifantis
NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia. Nature immunology 23 (10) (2022)
Brian R Shy, Vivasvan S Vykunta, Alvin Ha, Alexis Talbot, Theodore L Roth, David N Nguyen, Wolfgang G Pfeifer, Yan Yi Chen, Franziska Blaeschke, Eric Shifrut, Shane Vedova, Murad R Mamedov, Jing-Yi Jing Chung, Hong Li, Ruby Yu, David Wu, Jeffrey Wolf, Thomas G Martin, Carlos E Castro, Lumeng Ye, Jonathan H Esensten, Justin Eyquem, Alexander Marson
High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails. Nature biotechnology (2022)
Anaïs Schavgoulidze, Alexis Talbot, Aurore Perrot, Titouan Cazaubiel, Xavier Leleu, Salomon Manier, Laure Buisson, Sabrina Mahéo, Laura Do Souto Ferreira, Luka Pavageau, Cyrille Hulin, Jean-Pierre Marolleau, Laurent Voillat, Karim Belhadj, Marion Divoux, Borhane Slama, Sabine Brechignac, Margaret Macro, Anne Marie Stoppa, Laurence Sanhes, Frederique Orsini Piocelle, Jean Fontan, Marie-Lorraine Chretien, Hélène Demarquette, Mohamad Mohty, Herve Avet-Loiseau, Jill Corre
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor. Blood (2022)
Ian D Ferguson, Bonell Patiño Escobar, Sami T Tuomivaara, Yu-Hsiu Tony Lin, Matthew A Nix, Kevin K Leung, Corynn Kasap, Emilio Ramos, Wilson Nieves Vasquez, Alexis Talbot, Martina Hale, Akul Naik, Audrey Kishishita, Priya Choudhry, Antonia Lopez-Girona, Weili Miao, Sandy W Wong, Jeffrey L Wolf, Thomas G Martin, Nina Shah, Scott Vandenberg, Sonam Prakash, Lenka Besse, Christoph Driessen, Avery D Posey, R Dyche Mullins, Justin Eyquem, James A Wells, Arun P Wiita
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nature communications 13 (1) (2022)
Audrey Abecassis, Nathalie Roders, Maxime Fayon, Caroline Choisy, Elisabeth Nelson, Stephanie Harel, Bruno Royer, Camille Villesuzanne, Alexis Talbot, David Garrick, Michele Goodhardt, Jean-Christophe Bories, Mike Burbridge, Bertrand Arnulf, Jean-Christophe Bories
CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment. EJHaem 3 (3) (2022)
Daniel B Goodman, Camillia S Azimi, Kendall Kearns, Alexis Talbot, Kiavash Garakani, Julie M Garcia, Nisarg A Patel, Byungjin Hwang, David S Lee, Minhee Park, Vivasvan S Vykunta, Brian R Shy, Chun Jimmie Ye, Justin Eyquem, Alexander Marson, Jeffrey A Bluestone, Kole T Roybal
Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies. Science translational medicine 14 (670) (2022)
Alexis Claudel, Alexis Talbot, Stéphanie Harel, Bruno Royer, Lombion Naelle, Anne-Marie Zagdanski, Isabelle Madelaine, Pierre Lemaire, Bertrand Arnulf
Thiotepa intrathecal injections for myelomatous central nervous system involvement. British journal of haematology 193 (2) (2021)
Antoine David, Simone Zocchi, Alexis Talbot, Caroline Choisy, Ashley Ohnona, Julien Lion, Wendy Cuccuini, Jean Soulier, Bertrand Arnulf, Jean-Christophe Bories, Michele Goodhardt, David Garrick
The long non-coding RNA CRNDE regulates growth of multiple myeloma cells via an effect on IL6 signalling. Leukemia 35 (6) (2020)
Alexandre Terré, Alexis Talbot, Camille Louvrier, Jean Baptiste Picque, Matthieu Mahévas, David Boutboul, Serge Amselem, Irina Giurgea, Gilles Grateau, Stéphanie Ducharme-Bénard, null null
Monoclonal Gammopathy, Arthralgias, and Recurrent Fever Syndrome: A New Autoinflammatory Syndrome? The Journal of rheumatology 46 (11) (2019)